José Alberto
Arranz Caso
Profesor/a Asociado/a en CC. de la Salud
Universidad Complutense de Madrid
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Universidad Complutense de Madrid (9)
2021
-
A predictive model and risk factors for case fatality of covid-19
Journal of Personalized Medicine, Vol. 11, Núm. 1, pp. 1-18
2019
-
Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
Scientific Reports, Vol. 9, Núm. 1
2016
2009
-
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-Week analysis
Journal of Acquired Immune Deficiency Syndromes, Vol. 51, Núm. 2, pp. 147-152
2008
-
Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression
Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 6, pp. 1359-1361
-
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV
AIDS, Vol. 22, Núm. 2
2005
-
Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-Week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK study)
Journal of Acquired Immune Deficiency Syndromes, Vol. 40, Núm. 3, pp. 280-287
2004
-
Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load
Clinical Infectious Diseases, Vol. 39, Núm. 7, pp. 1024-1029